Eli Lilly completes acquisition of Adverum Biotechnologies
Source: SeekingAlpha
2025-12-09 09:29:13 ET
More on Eli Lilly, Adverum Biotechnologies
- Mounjaro In China: Assessing Market Potential And Risks
- Eli Lilly and Company (LLY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
- Eli Lilly: The GLP-1 Leader's Sky-High P/E Makes It A Clear Hold
- Lilly's Jaypirca succeeds in late-stage trial as a first-line option in lymphoma
- Eli Lilly, Pfizer drugs added to China's state insurance list
Read the full article on Seeking Alpha
For further details see:
Eli Lilly completes acquisition of Adverum Biotechnologies
Adverum Biotechnologies Inc.
NASDAQ: ADVM
ADVM Trading
-18.98% G/L:
$4.31 Last:
214,266 Volume:
$4.24 Open:
ADVM Latest News
December 09, 2025 08:28:00 am
Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition
December 01, 2025 07:00:00 am
Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly
November 19, 2025 06:18:00 pm
Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights
ADVM Stock Data
$96,257,756
15,123,064
8.87%
54
N/A
Biotechnology & Life Sciences
Healthcare
US
Redwood City
